Faster global financial news!
Eli Lilly
-
24/7 Wall St. Analysts: Eli Lilly (LLY) Market Cap Exceeds $1 Trillion, Stock Expected to Rise Another 8.58% in Next 12 Months, Maintain "Buy" Rating
Analysts noted that Eli Lilly and Company's revenue reached $22.974 billion in Q2 2026, a 47.67% year-over-year increase, with earnings per share (EPS) of $8.38, exceeding market expectations by 27.27
-
Pharmaceutical stocks generally performed poorly, but Eli Lilly's stock remained strong; Boeing's delivery situation was mixed.
Pharmaceutical stocks generally performed poorly, but Eli Lilly's stock remained strong; Boeing's delivery situation was mixed.
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Billionaire Ken Griffin's Citadel fund nearly quadrupled its stake in Eli Lilly (LLY.US) in the second quarter, adding approximately 740,000 shares.
Ken Griffin's Citadel fund significantly increased its stake in pharmaceutical giant Eli Lilly in the second quarter of this year, making it one of the fund's top holdings. Eli Lilly is currently at t
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
DeItaone reports that Eli Lilly (LLY) delivered strong Q2 results, exceeding expectations, and raised its full-year revenue guidance to $85.0-$87.0 billion, with adjusted EPS guidance of $35.50-$36.50.
Eli Lilly's Q2 adjusted EPS was $8.38, significantly exceeding the expected $6.01; revenue reached $22.97 billion, higher than the anticipated $20.73 billion. Of this, Mounjaro revenue was $9.94 billi
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
JPMorgan says one of the market’s ‘most durable growth’ sectors has been passed over for AI
JPMorgan states that one of the market’s “most durable growth” sectors has been overlooked by investors in favor of artificial intelligence (AI). The bank lists Eli Lilly, AbbVie, and Danaher Corporat
-
24/7 Wall St. Analysts: Eli Lilly (LLY) Market Cap Exceeds $1 Trillion, Stock Expected to Rise Another 8.58% in Next 12 Months, Maintain "Buy" Rating
Analysts noted that Eli Lilly and Company's revenue reached $22.974 billion in Q2 2026, a 47.67% year-over-year increase, with earnings per share (EPS) of $8.38, exceeding market expectations by 27.27
-
Pharmaceutical stocks generally performed poorly, but Eli Lilly's stock remained strong; Boeing's delivery situation was mixed.
Pharmaceutical stocks generally performed poorly, but Eli Lilly's stock remained strong; Boeing's delivery situation was mixed.
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Billionaire Ken Griffin's Citadel fund nearly quadrupled its stake in Eli Lilly (LLY.US) in the second quarter, adding approximately 740,000 shares.
Ken Griffin's Citadel fund significantly increased its stake in pharmaceutical giant Eli Lilly in the second quarter of this year, making it one of the fund's top holdings. Eli Lilly is currently at t
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
DeItaone reports that Eli Lilly (LLY) delivered strong Q2 results, exceeding expectations, and raised its full-year revenue guidance to $85.0-$87.0 billion, with adjusted EPS guidance of $35.50-$36.50.
Eli Lilly's Q2 adjusted EPS was $8.38, significantly exceeding the expected $6.01; revenue reached $22.97 billion, higher than the anticipated $20.73 billion. Of this, Mounjaro revenue was $9.94 billi
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
JPMorgan says one of the market’s ‘most durable growth’ sectors has been passed over for AI
JPMorgan states that one of the market’s “most durable growth” sectors has been overlooked by investors in favor of artificial intelligence (AI). The bank lists Eli Lilly, AbbVie, and Danaher Corporat
- No data
Eli Lilly
24H Trending
-
1
Aethir (ATH) Token Value Analysis: Decentralized Cloud Computing Project Potential and Risk Assessment
-
2
Bitcoin rises above $77,000, bucking tech selloff driven by AI safety concerns and rising oil prices
-
3
Guyana's President: Oil Revenue Surges Due to Iran Conflict
-
4
NOAH Coin Analysis: Distinguishing Between Controversial Projects and Active Payment Infrastructure
-
5
RIKEN Coin Value Analysis: Numerous Projects Share the Same Name, What's Its Investment Potential?
-
6
FXBK Coin Analysis: What Is It? Is It Worth Investing In?
-
7
Cosco Shipping Heavy Industry Completes China IPO Guidance Registration
-
8
Beginner's Guide to Bitcoin Trading: A Comprehensive Analysis of Security Risks and Prevention Strategies
-
9
Taiwan to open second quasi-diplomatic mission in the Philippines, sources say
-
10
Samsung Display develops world's first 6.9-inch mobile OLED panel with 2K resolution, 165Hz refresh rate, and 30% lower power consumption
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
